Please assess the completion status of the following clinical trial:

Trial Title: STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject has a diagnosis of Pompe disease based on documented deficiency of GAA activity and a documented GAA mutation.~2. Male and female subjects between 18 years and 75 years, inclusive and ≥ 50 kg.~3. Subject must be currently receiving standard-of-care ERT (alglucosidase alfa) at a dose of 20 mg/kg dose every other week.~4. Subject must have been on ERT for the preceding 2 years or more.~5. Subject must have an upright forced vital capacity (FVC) within 35 to 90% of predicted normal (NHANES III reference values), based on the higher of the screening or baseline value, if their 6 minute walk distance (6MWD) is \> 200 m. Subject must have an upright FVC within 40 to 90% of predicted normal (NHANES III reference values), based on the higher of the screening or baseline value, if their 6MWD is ≤ 200 m. If FVC is between 80 and 90% of predicted normal, the subject may enter the study if the percent predicted FVC value drops by 10% predicted or more in supine position~6. Subject is able to walk at least 100 m in the 6MWT and the assessment is noted as valid.~Exclusion Criteria:~1. Subject has received any investigational therapy or pharmacological treatment for Pompe disease, other than alglucosidase alfa within 30 days or 5 half lives, whichever is shorter, prior to the Baseline Visit or is anticipated to do so during the course of the study~2. Subject is on any of the following prohibited medications within 30 days of baseline:~   * miglitol (eg, Glyset)~  * miglustat (eg, Zavesca)~  * acarbose (eg, Precose, Glucobay)~  * voglibose (eg, Volix, Vocarb, Volibo)~3. Subject requires use of invasive or non-invasive ventilatory support for \> 6 hours a day while awake.~4. Subject has a medical or any other extenuating condition or circumstance that may, in the opinion of the investigator, pose an undue safety risk to the subject or compromise his/her ability to comply with protocol requirements. This includes clinical depression (as diagnosed by a psychiatrist or other mental health professional) with uncontrolled or poorly controlled symptoms.~5. Subject is breastfeeding, or is pregnant or planning to become pregnant within the next 2 years.~6. Other exclusion criteria according to the Lumizyme/Myozyme instructions for use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).